Crinetics Pharmaceuticals Inc (CRNX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Scott R. Struthers
Employees:
210
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA 92121
858-450-6464

Crinetics Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism.

Data derived from most recent annual or quarterly report
Market Cap 1.6 Billion Shares Outstanding54.026 Million Avg 30-day Volume 3.128 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.94
Price to Revenue200.9594 Debt to Equity0.0 EBITDA-192.816 Million
Price to Book Value3.8228 Operating Margin-3971.5143 Enterprise Value706.909 Million
Current Ratio8.734 EPS Growth-0.153 Quick Ratio8.112
1 Yr BETA 1.0255 52-week High/Low 31.0 / 15.23 Profit Margin-3804.096
Operating Cash Flow Growth-77.7525 Free Cash Flow to Firm (FCFF) TTM -146.316 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score11.221
Earnings Report2023-11-09
View SEC Filings from CRNX instead.

View recent insider trading info

Funds Holding CRNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRNX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-09-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-11:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-28:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    10 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    STRUTHERS RICHARD SCOTT PRESIDENT & CEO

    • Officer
    • Director
    857,327 2023-08-14 6

    WILSON MARC CFO

    • Officer
    95,158 2023-06-20 4

    WIERENGA WENDALL

    • Director
    105,846 2023-06-16 1

    BEDROSIAN CAMILLE L

    • Director
    6,000 2023-06-16 1

    FUST MATTHEW K

    • Director
    18,536 2023-06-16 1

    VIVALDI COELHO ROGERIO

    • Director
    11,000 2023-06-16 2

    OKEY STEPHANIE

    • Director
    6,000 2023-06-16 1

    NICHOLS WESTON

    • Director
    6,000 2023-06-16 1

    DEARDORF CAREN

    • Director
    6,000 2023-06-16 1

    PIZZUTI DANA CHIEF DEVELOPMENT OFFICER

    • Officer
    4,500 2023-04-03 4

    KRASNER ALAN SETH CHIEF MEDICAL OFFICER

    • Officer
    42,301 2023-03-16 3

    KNIGHT JEFF E. CHIEF OPERATING OFFICER

    • Officer
    34,400 2023-03-16 3

    BETZ STEPHEN F. CHIEF SCIENTIFIC OFFICER

    • Officer
    86,879 2023-03-16 12

    HASSARD JAMES CHIEF COMMERCIAL OFFICER

    • Officer
    14,000 2023-03-01 1

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • 10% Owner
    5,321,032 2022-04-18 0

    MADAN AJAY CHIEF DEVELOPMENT OFFICER

    • Officer
    428,390 2022-02-28 0

    KALDOR STEPHEN W

    • Director
    0 2020-06-19 0

    VIVO CAPITAL VIII, LLC

    VIVO CAPITAL FUND VIII, L.P.

    VIVO CAPITAL SURPLUS FUND VIII, L.P.

    • 10% Owner
    No longer subject to file 2020-04-15 0

    VIVO CAPITAL VIII, LLC

    VIVO CAPITAL FUND VIII, L.P.

    VIVO CAPITAL SURPLUS FUND VIII, L.P.

    VIVO OPPORTUNITY, LLC

    VIVO OPPORTUNITY FUND, L.P.

    • 10% Owner
    3,266,090 2020-03-09 0

    5AM VENTURES IV, L.P.

    5AM CO-INVESTORS IV, L.P.

    5AM PARTNERS IV, LLC

    ROCKLAGE SCOTT M

    DIEKMAN JOHN D

    SCHWAB ANDREW J.

    • FORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDER
    No longer subject to file 2019-06-21 0

    NIELSEN JACK

    • Director
    0 2019-06-21 0

    VERSANT VENTURE CAPITAL V, L.P.

    VERSANT AFFILIATES FUND V, L.P.

    VERSANT OPHTHALMIC AFFILIATES I, L.P.

    VERSANT VENTURE CAPITAL V (CANADA), LP

    VERSANT VENTURES V, LLC

    VERSANT VENTURES V (CANADA), L.P.

    • 10% Owner
    2,876,688 2019-02-04 0

    VERSANT VENTURE CAPITAL V, L.P.

    VERSANT AFFILIATES FUND V, L.P.

    VERSANT OPHTHALMIC AFFILIATES I, L.P.

    VERSANT VENTURE CAPITAL V (CANADA), LP

    • 10% Owner
    6,298,477 2018-07-20 0

    VIVO CAPITAL VIII, LLC

    VIVO CAPITAL, LLC

    VIVO CAPITAL FUND VIII, L.P.

    VIVO CAPITAL SURPLUS FUND VIII, L.P.

    VIVO OPPORTUNITY, LLC

    VIVO OPPORTUNITY FUND, L.P.

    • 10% Owner
    3,737,458 2018-07-20 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    • 10% Owner
    0 2018-07-17 0

    VIVO CAPITAL VIII, LLC

    VIVO CAPITAL, LLC

    VIVO CAPITAL FUND VIII, L.P.

    VIVO CAPITAL SURPLUS FUND VIII, L.P.

    • 10% Owner
    54,711 2018-07-17 0

    FREEMAN MASON

    • Director
    0 2018-07-17 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    STRUTHERS RICHARD SCOTT - Director - Officer PRESIDENT & CEO

    2023-08-16 16:30:15 -0400 2023-08-14 M 10,000 $1.91 a 135,522 direct -0.4318 6.0457 11.0426 5 -0.987 3

    STRUTHERS RICHARD SCOTT - Director - Officer PRESIDENT & CEO

    2023-08-16 16:30:15 -0400 2023-08-14 M 10,000 d 151,270 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 22:15:04 UTC 4.8361 0.4839 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 21:45:04 UTC 4.8361 0.4839 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 21:15:04 UTC 4.8361 0.4839 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 20:45:04 UTC 4.8361 0.4839 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 20:15:04 UTC 4.8361 0.4839 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 19:45:04 UTC 4.8361 0.4839 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 19:15:04 UTC 4.9044 0.4156 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 18:45:04 UTC 4.9044 0.4156 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 18:15:03 UTC 4.9044 0.4156 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 17:45:04 UTC 4.9044 0.4156 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 17:15:03 UTC 4.9044 0.4156 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 16:45:04 UTC 4.7478 0.5722 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 16:15:03 UTC 4.7478 0.5722 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 15:45:03 UTC -5.9892 11.3092 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 15:15:04 UTC -5.9892 11.3092 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 14:45:04 UTC -5.9892 11.3092 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 14:15:04 UTC -5.9892 11.3092 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 13:45:04 UTC -5.9892 11.3092 1000000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 13:15:04 UTC -5.9892 11.3092 950000
    CRINETICS PHARMACEUTICALS IN CRNX 2023-09-25 12:45:06 UTC -5.9892 11.3092 950000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund CRNX -7.0 shares, $-102.9 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund CRNX -4.0 shares, $-58.8 2020-03-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund CRNX -8669.0 shares, $-169392.26 2023-04-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments